Under the agreement, Gland Pharma will serve as an integrated end-to-end partner for multiple products across different stages of the product lifecycle, including commercially marketed and pipeline products under development. The collaboration follows a full-service contract development and manufacturing organization (CDMO) model covering technology transfer, process development, scale-up, validation, commercial manufacturing and long-term supply of sterile injectable products. Under the agreement, Gland Pharma will leverage its capabilities across development, technology transfer, manufacturing, quality and regulatory support to provide an integrated solution to the partner. The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma's development, technology transfer, manufacturing, and supply capabilities,” said Srinivas Sadu, Executive Chairman, Gland Pharma. The company primarily operates under a CDMO and business-to-business (B2B) model and has capabilities in developing, manufacturing and marketing sterile injectable products.